BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32124501)

  • 1. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
    Deng Y; Guo W; Xu N; Li F; Li J
    Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
    Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
    Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
    Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
    Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
    Deng Y; Deng H; Liu J; Han G; Malkoski S; Liu B; Zhao R; Wang XJ; Zhang Q
    Mol Carcinog; 2012 Jun; 51(6):500-7. PubMed ID: 21681822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells.
    Jin W; Scotto KW; Hait WN; Yang JM
    Biochem Pharmacol; 2007 Sep; 74(6):851-9. PubMed ID: 17662696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
    Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y
    Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
    Tian J; Lin Y; Yu J
    Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
    Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of transcriptional corepressor CtBP1 in prostate cancer progression.
    Wang R; Asangani IA; Chakravarthi BV; Ateeq B; Lonigro RJ; Cao Q; Mani RS; Camacho DF; McGregor N; Schumann TE; Jing X; Menawat R; Tomlins SA; Zheng H; Otte AP; Mehra R; Siddiqui J; Dhanasekaran SM; Nyati MK; Pienta KJ; Palanisamy N; Kunju LP; Rubin MA; Chinnaiyan AM; Varambally S
    Neoplasia; 2012 Oct; 14(10):905-14. PubMed ID: 23097625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
    Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
    J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evidence for Eme1 as a marker of cisplatin resistance.
    Tomoda Y; Katsura M; Okajima M; Hosoya N; Kohno N; Miyagawa K
    Int J Cancer; 2009 Jun; 124(12):2997-3001. PubMed ID: 19267403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer.
    Choi HJ; Lee JM; Kim H; Nam HJ; Shin HJ; Kim D; Ko E; Noh DY; Kim KI; Kim JH; Baek SH
    Biochem Biophys Res Commun; 2010 Sep; 400(3):396-402. PubMed ID: 20800578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression.
    Wu Y; Zhao H
    Oncol Lett; 2021 Nov; 22(5):810. PubMed ID: 34630717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
    Li C; Xiao XQ; Qian YH; Zhou ZY
    J Cell Physiol; 2019 Dec; 234(12):22365-22377. PubMed ID: 31074088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
    Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
    Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice.
    Moiola CP; De Luca P; Zalazar F; Cotignola J; Rodríguez-Seguí SA; Gardner K; Meiss R; Vallecorsa P; Pignataro O; Mazza O; Vazquez ES; De Siervi A
    Clin Cancer Res; 2014 Aug; 20(15):4086-95. PubMed ID: 24842953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
    Zhou C; Huang P; Liu J
    Biochem Biophys Res Commun; 2005 Oct; 336(3):952-60. PubMed ID: 16165098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.
    Deng H; Liu J; Deng Y; Han G; Shellman YG; Robinson SE; Tentler JJ; Robinson WA; Norris DA; Wang XJ; Zhang Q
    J Invest Dermatol; 2013 May; 133(5):1294-301. PubMed ID: 23303449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.